Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

5-Day brain zapping trial aims to lift severe depression

NCT ID NCT06895863

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 27, 2026 · Updated 2 times

Summary

This trial tests a new, accelerated form of brain stimulation for people with severe depression that hasn't improved with medication. Over five days, 78 participants will receive 25 sessions of magnetic stimulation, either targeting a standard brain area or a new one, or a sham (fake) treatment. The goal is to see if this fast, personalized approach can safely and quickly ease depression symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial magnetic stimulation (TMS) using intermittent theta burst stimulation (iTBS)
What this could lead to
If it works, this could offer a fast, non-invasive treatment option for people with severe depression that hasn't responded to medication.
What could go wrong
This is a relatively small, early-stage trial testing two different brain targets. It's not yet proven to work, and the effects may be modest or not last long.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 78 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 95 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Age range between 18 and 95 years * In- or outpatients with a moderate to severe single episode or periodic MDD according to ICD-10, verified by a M.I.N.I. interview. * Major Depression Inventory (self-rapport) score higher than 25. * Lacking or insufficient effect of at least two drug trials from two distinct classes, e.g., SSRI, SNRI, TCA, or MAO-inhibitors, used in the current episode, with adequate dose and duration as judged by the investigator. * Duration of the current episode must be longer than 2 months but shorter than 4 years, as judged by the investigator. Exclusion criteria: * History of neurologic disease affecting the brain, including dementia and epilepsy * Schizophrenia or any other psychotic disorder except for psychotic depression * Head trauma causing more than 5 minutes loss of consciousness * Suicidal or psychotic symptoms making the transport of participants hazardous * Any form of compulsory admission or treatment within the past three months * Treatment with ECT in the current depressive episode * Non-responders to TBS treatment within the current episode * Current harmful use or dependency of substances according to ICD-10 and interfering with outcome evaluation as judged by investigator's discretion. * High risk of non-adherence as judged by investigators discretion * Medical and psychiatric conditions interfering with study outcome and safety as judged by investigator's discretion. * Female participants of childbearing age must not be pregnant or breast feeding, and they must use contraception during the trial. * One of the prime contra-indications for MRI, including severe claustrophobia (see Appendix 08.05) * One of the prime contra-indications for TMS and persons with electrically, magnetically, or mechanically activated implants or with metal or magnetic pieces in their head (see Appendix 08.04) * Patients who do not wish to be informed about MRI or EEG findings, which may have clinical relevance.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Treatment-resistant depression are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depressive Disorder, Treatment-Resistant major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre of Neuropsychiatric Depression Research

    RECRUITING

    Glostrup Municipality, 2600, Denmark

  • Danish Research Centre for Magnetic Resonance

    NOT_YET_RECRUITING

    Hvidovre, 2650, Denmark

  • Mental Health Center North Zealand

    NOT_YET_RECRUITING

    Hilleroed, 3400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.